IN172553B - - Google Patents

Info

Publication number
IN172553B
IN172553B IN905MA1990A IN172553B IN 172553 B IN172553 B IN 172553B IN 905MA1990 A IN905MA1990 A IN 905MA1990A IN 172553 B IN172553 B IN 172553B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Joseph Armstrong Martin
Sally Redshaw
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN172553B publication Critical patent/IN172553B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Confectionery (AREA)
  • Cleaning Or Clearing Of The Surface Of Open Water (AREA)
  • Measurement Of Force In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
IN905MA1990 1989-12-11 1990-11-12 IN172553B (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898927913A GB8927913D0 (en) 1989-12-11 1989-12-11 Amino acid derivatives
SG120493A SG120493G (en) 1989-12-11 1993-11-02 N-tert-Butyl-decahydro-2(3-amino-2-hydroxy-4-phenyl-butyl) isoquinoline-3-carboxamide and asparaginyl derivatives thereof

Publications (1)

Publication Number Publication Date
IN172553B true IN172553B (cg-RX-API-DMAC7.html) 1993-09-25

Family

ID=26296345

Family Applications (1)

Application Number Title Priority Date Filing Date
IN905MA1990 IN172553B (cg-RX-API-DMAC7.html) 1989-12-11 1990-11-12

Country Status (48)

Country Link
US (1) US5196438A (cg-RX-API-DMAC7.html)
EP (1) EP0432695B1 (cg-RX-API-DMAC7.html)
JP (1) JP2807093B2 (cg-RX-API-DMAC7.html)
KR (1) KR970005912B1 (cg-RX-API-DMAC7.html)
CN (2) CN1066329C (cg-RX-API-DMAC7.html)
AT (1) ATE122661T1 (cg-RX-API-DMAC7.html)
AU (1) AU634319B2 (cg-RX-API-DMAC7.html)
BG (1) BG51452A3 (cg-RX-API-DMAC7.html)
BR (1) BR9006264A (cg-RX-API-DMAC7.html)
CA (1) CA2030433C (cg-RX-API-DMAC7.html)
CU (1) CU22305A3 (cg-RX-API-DMAC7.html)
CZ (1) CZ280558B6 (cg-RX-API-DMAC7.html)
DE (2) DE69019481T2 (cg-RX-API-DMAC7.html)
DK (1) DK0432695T3 (cg-RX-API-DMAC7.html)
DZ (1) DZ1467A1 (cg-RX-API-DMAC7.html)
EG (1) EG19722A (cg-RX-API-DMAC7.html)
ES (1) ES2072959T3 (cg-RX-API-DMAC7.html)
FI (2) FI973895A7 (cg-RX-API-DMAC7.html)
GB (2) GB8927913D0 (cg-RX-API-DMAC7.html)
GR (1) GR3017114T3 (cg-RX-API-DMAC7.html)
HK (1) HK129093A (cg-RX-API-DMAC7.html)
HR (1) HRP930341B1 (cg-RX-API-DMAC7.html)
HU (2) HU207298B (cg-RX-API-DMAC7.html)
ID (1) ID1018B (cg-RX-API-DMAC7.html)
IE (1) IE67523B1 (cg-RX-API-DMAC7.html)
IL (1) IL96550A (cg-RX-API-DMAC7.html)
IN (1) IN172553B (cg-RX-API-DMAC7.html)
IS (1) IS1803B (cg-RX-API-DMAC7.html)
LT (1) LT3682B (cg-RX-API-DMAC7.html)
LU (1) LU90014I2 (cg-RX-API-DMAC7.html)
LV (1) LV5738B4 (cg-RX-API-DMAC7.html)
MA (1) MA22014A1 (cg-RX-API-DMAC7.html)
MC (1) MC2195A1 (cg-RX-API-DMAC7.html)
MT (1) MTP1075B (cg-RX-API-DMAC7.html)
MW (1) MW8890A1 (cg-RX-API-DMAC7.html)
MX (1) MX173630B (cg-RX-API-DMAC7.html)
NL (1) NL970013I2 (cg-RX-API-DMAC7.html)
NO (1) NO176566C (cg-RX-API-DMAC7.html)
OA (1) OA09334A (cg-RX-API-DMAC7.html)
PL (1) PL165225B1 (cg-RX-API-DMAC7.html)
PT (1) PT96145B (cg-RX-API-DMAC7.html)
RO (1) RO107942B1 (cg-RX-API-DMAC7.html)
RU (1) RU2071470C1 (cg-RX-API-DMAC7.html)
SG (1) SG120493G (cg-RX-API-DMAC7.html)
SI (1) SI9012315B (cg-RX-API-DMAC7.html)
SK (1) SK576590A3 (cg-RX-API-DMAC7.html)
ZA (1) ZA909743B (cg-RX-API-DMAC7.html)
ZW (1) ZW17490A1 (cg-RX-API-DMAC7.html)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US20040122000A1 (en) * 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US5614533A (en) * 1987-03-13 1997-03-25 Bio-Mega/Boehringer Ingelheim Research, Inc. Substituted pipecolinic acid derivatives as HIV protease inhibitors
USH1649H (en) 1987-07-31 1997-05-06 Barrish; Joel C. HIV protease inhibitor combinations
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
US5430041A (en) * 1991-05-10 1995-07-04 Hoffmann-La Roche Inc. Amino acid derivatives having antiviral activity
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
US5508407A (en) * 1991-07-10 1996-04-16 Eli Lilly And Company Retroviral protease inhibitors
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
EP0541168B1 (en) * 1991-11-08 1998-03-11 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
RU2126794C1 (ru) 1992-03-11 1999-02-27 Нархекс Лимитед Аминопроизводные оксо- или гидроксизамещенных гидразинов, способ их получения и фармацевтические композиции для ингибирования ретровирусной протеазы
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
DK0560268T3 (da) * 1992-03-13 1995-06-12 Bio Mega Boehringer Ingelheim Substituerede pipecolinsyrederivater som HIV-proteasehæmmere
EP1447398A1 (en) * 1992-05-21 2004-08-18 Monsanto Company Retroviral protease inhibitors
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
DE69332002T2 (de) 1992-08-25 2002-12-19 Monsanto Co Hydroxyethylaminosulfonamide verwendbar als Inhibitoren retroviraler Proteasen
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
TW372972B (en) * 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
US5380849A (en) * 1992-11-09 1995-01-10 Merck & Co., Inc. Process for optically pure decahydroisoqiunolines
US5430150A (en) * 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5434265A (en) * 1992-12-22 1995-07-18 Eli Lilly And Company Inhibitors of HIV protease
MX9308025A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5733906A (en) * 1993-10-12 1998-03-31 Eli Lilly And Company Inhibitors of HIV Protease useful for the treatment of Aids
MX9308016A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
US5491166A (en) * 1992-12-22 1996-02-13 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
US5693815A (en) * 1993-01-17 1997-12-02 Schering Corporation Peptides
US5939430A (en) * 1993-02-22 1999-08-17 Merrell Pharmaceuticals Inc. Combinations of retroviral inhibitors
US5455353A (en) * 1993-03-24 1995-10-03 Hoffmann-La Roche Inc. 4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides
ATE172970T1 (de) * 1993-07-15 1998-11-15 Hoffmann La Roche Verfahren zur herstellung eines n-tert.butylamids
DE69426655T2 (de) * 1994-02-02 2001-06-13 Eli Lilly And Co., Indianapolis Hiv-protease inhibitoren und zwischenprodukte
US6127372A (en) * 1994-03-07 2000-10-03 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5470979A (en) * 1994-07-01 1995-11-28 American Cyanamid Company Asymmetric synthesis of bicyclic amino acid esters
US5591885A (en) * 1994-09-23 1997-01-07 Hoffman-La Roche Inc. Process for the preparation of halogenated α-aminoketone compounds
US5523463A (en) * 1994-09-23 1996-06-04 Hoffmann-La Roche Inc. Method of producing halogenated and alpha-aminoalchohols
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
MX9709193A (es) * 1995-06-06 1998-03-31 Hoffmann La Roche Monogliceridos y un inhibidor de proteinasa que comprende la composicion farmaceutica.
US6004957A (en) * 1995-06-07 1999-12-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
AU759386B2 (en) * 1995-06-29 2003-04-10 Abbvie Inc. Use of Ritonavir (ABT-538) for improving the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treating AIDS
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
DE69634959T2 (de) 1995-11-13 2006-05-24 Vitaleech Bioscience N.V. Antivirale isolate von blutegeln
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5883252A (en) * 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
US5587481A (en) * 1996-02-20 1996-12-24 The Monsanto Company Preparation of (S)-decahydroisoquinoline-3-carboxylic acid t-butylamide
US5914404A (en) * 1996-08-09 1999-06-22 Hoffmann-La Roche Inc. Process for the preparation of quinargine
EP0823424A1 (de) * 1996-08-09 1998-02-11 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von Chinargin
US5962725A (en) * 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
EP0847994B1 (de) 1996-12-11 2003-04-09 F. Hoffmann-La Roche Ag Verfahren zur Herstellung gemischter Anhydride
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6143742A (en) * 1997-12-11 2000-11-07 Fuisz Technologies Ltd Treatment for necrotizing infections
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
WO1999065870A2 (en) 1998-06-19 1999-12-23 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of aspartyl protease
JP3353784B2 (ja) * 1998-10-21 2002-12-03 藤沢薬品工業株式会社 公知のブラジキニン拮抗剤のガラス体
KR100277723B1 (ko) 1998-12-14 2001-01-15 남창우 광학적으로 순수한 데카하이드로이소퀴놀린카르복사미드의 연속제조공정
US7635690B2 (en) * 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7115584B2 (en) * 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US6765019B1 (en) 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
SI1733725T2 (sl) * 1999-06-04 2012-10-30 Abbott Lab Farmacevtske formulacije, vsebujoče vsaj eno spojino za inhibicijo HIV proteaze
US6589962B1 (en) 1999-07-20 2003-07-08 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
WO2001005230A1 (en) * 1999-07-20 2001-01-25 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
AU777824B2 (en) 1999-11-24 2004-11-04 Merck Sharp & Dohme Corp. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1- piperazinepentanamides as HIV protease inhibitors
IT1313682B1 (it) * 1999-11-25 2002-09-09 Archimica Spa Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
DE60038899D1 (de) 2000-01-19 2008-06-26 Abbott Lab Hiv-proteasehemmern
US6448245B1 (en) 2000-05-04 2002-09-10 The United States Of America As Represented By The Department Of Health And Human Services Methods of and compounds for inhibiting calpains
IT1318986B1 (it) * 2000-10-09 2003-09-19 Archimica S P A Ora Clariant L Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
GB0028483D0 (en) 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
US20030191121A1 (en) * 2001-08-09 2003-10-09 Miller Ross A. Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
EP1463807A4 (en) 2001-12-19 2006-04-12 Bristol Myers Squibb Co FORMATHYDROGENASE FROM PICHIA PASTORIS AND USES THEREOF
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
EP1515944A1 (en) * 2002-06-17 2005-03-23 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
US7115652B2 (en) * 2002-06-17 2006-10-03 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
NZ544585A (en) * 2003-07-11 2008-04-30 Hoffmann La Roche Saquinavir mesylate oral dosage form
EP1604662A1 (en) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus
BRPI0512690A (pt) 2004-07-27 2007-11-27 Gilead Sciences Inc análogos de fosfonato de compostos inibidores de hiv
WO2006134612A1 (en) * 2005-06-16 2006-12-21 Hetero Drugs Limited A process for the preparation of saquinavir using novel intermediate
CA2679482C (en) 2007-03-12 2015-04-21 Nektar Therapeutics Oligomer-protease inhibitor conjugates
JP5547066B2 (ja) * 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療用組成物およびその使用
JP5547067B2 (ja) * 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療組成物およびその使用
US20100093811A1 (en) * 2007-09-25 2010-04-15 Coburn Craig A Hiv protease inhibitors
EP2262538B1 (en) * 2008-03-12 2014-12-10 Nektar Therapeutics Oligomer-amino acid conjugate
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CN103497192B (zh) 2008-12-09 2015-09-23 吉里德科学公司 Toll样受体调节剂
EA019341B1 (ru) * 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Фосфорамидаты нуклеозидов
BRPI0923815A2 (pt) 2008-12-23 2015-07-14 Pharmasset Inc Síntese de nucleosídeos de purina
EP2376514A2 (en) * 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
US8497383B2 (en) 2009-05-27 2013-07-30 Merck Sharp & Dohme Corp. HIV protease inhibitors
WO2010144869A2 (en) 2009-06-12 2010-12-16 Nektar Therapeutics Protease inhibitors
DE102010004957A1 (de) 2010-01-14 2011-07-21 Universitätsklinikum Jena, 07743 Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
LT2609923T (lt) 2010-03-31 2017-09-11 Gilead Pharmasset Llc (s)-izopropilo 2-(((s)-(perfluorfenoksi)(fenoksi)fosforil)amino)-propanoato kristalinimo būdas
EP2632895B1 (en) 2010-10-28 2018-10-03 Merck Canada Inc. Hiv protease inhibitors
EP2392926A1 (en) 2011-02-09 2011-12-07 Roche Diagnostics GmbH Urinary biomarkers in HIV infected subjects
WO2013059928A1 (en) 2011-10-26 2013-05-02 Merck Canada Inc. Hiv protease inhibitors
IN2012DE00082A (cg-RX-API-DMAC7.html) 2012-01-10 2015-05-01 Council Scient Ind Res
RU2015113091A (ru) 2012-09-11 2016-11-10 Мерк Шарп И Доум Корп. Ингибиторы протеазы вич
AU2013340559B2 (en) 2012-10-29 2018-03-15 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
US9834526B2 (en) 2013-12-19 2017-12-05 Merck Sharp & Dohme Corp. HIV protease inhibitors
WO2015095265A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP3113780B1 (en) 2014-03-06 2019-08-14 Merck Sharp & Dohme Corp. Hiv protease inhibitors
US10138255B2 (en) 2014-03-10 2018-11-27 Merck Sharp & Dohme Corp. Piperazine derivatives as HIV protease inhibitors
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
WO2016069955A1 (en) 2014-10-29 2016-05-06 Wisconsin Alumni Research Foundation Boronic acid inhibitors of hiv protease
AU2016322763A1 (en) 2015-09-15 2018-04-19 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of HIV
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933968A (en) * 1960-10-26 1963-08-14 May & Baker Ltd New phthalimide derivatives
US4123543A (en) * 1971-09-16 1978-10-31 Ab Kabi Derivatives of substituted indoline lactans with effect on the central nervous system
US3901897A (en) * 1972-10-05 1975-08-26 Squibb & Sons Inc 1,2,3,4,4a,5,6,7-octahydro-7-aryl-isoquinolines and derivatives thereof
US4329473A (en) * 1979-06-01 1982-05-11 Almquist Ronald G Oxoalkanoic acid derivatives as inhibitors of angiotensin converting enzyme
SE421551B (sv) * 1980-03-26 1982-01-04 Sandvik Ab Borrverktyg for rotations- och/eller slagborrning
US4470973A (en) * 1982-07-19 1984-09-11 E. R. Squibb & Sons, Inc. Substituted peptide compounds
US4812442A (en) * 1984-05-29 1989-03-14 Merck & Co., Inc. Tripeptide renin inhibitors
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AT383762B (de) * 1985-12-23 1987-08-25 Plansee Metallwerk Verfahren zur herstellung mehrkomponentiger, kongruent erschmelzender lotmaterialien
CA1286989C (en) * 1985-12-26 1991-07-30 A. Arthur Gottlieb Immunoamplifiers and related compositions
WO1988000939A1 (fr) * 1986-07-25 1988-02-11 Banyu Pharmaceutical Co., Ltd. Derives d'amino-alcools optiquement actifs et procede pour leur preparation
DE3789347D1 (de) * 1986-10-14 1994-04-21 Banyu Pharma Co Ltd 5-Substituierte Amino-4-hydroxy-pentansäure-Derivate und deren Verwendung.
US4863905A (en) * 1987-02-04 1989-09-05 Warner-Lambert Company Renin inhibitors II
FR2610934B1 (fr) * 1987-02-13 1989-05-05 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE3717631A1 (de) * 1987-05-26 1988-12-15 Merck Patent Gmbh Aminosaeurederivate
DE3733296A1 (de) * 1987-10-02 1989-04-20 Merck Patent Gmbh Aminosaeurederivate
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
DE4033062A1 (de) * 1990-10-18 1992-04-23 Merck Patent Gmbh Aminosaeurederivate
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols

Also Published As

Publication number Publication date
JPH03255076A (ja) 1991-11-13
LT3682B (en) 1996-01-25
NO905322D0 (no) 1990-12-10
SK280249B6 (sk) 1999-10-08
SG120493G (en) 1994-01-21
KR970005912B1 (en) 1997-04-22
MA22014A1 (fr) 1991-07-01
CN1066329C (zh) 2001-05-30
JP2807093B2 (ja) 1998-09-30
IS1803B (is) 2002-02-26
OA09334A (fr) 1992-09-15
EG19722A (en) 1996-01-31
DE19675051I2 (de) 2001-04-12
GB2239016A (en) 1991-06-19
AU6787690A (en) 1991-06-13
MC2195A1 (fr) 1992-10-05
GB2239016B (en) 1993-08-04
AU634319B2 (en) 1993-02-18
IE904453A1 (en) 1991-06-19
CZ576590A3 (en) 1995-11-15
CN1138983A (zh) 1997-01-01
HU211342A9 (en) 1995-11-28
RU2071470C1 (ru) 1997-01-10
SI9012315A (en) 1997-10-31
SK576590A3 (en) 1999-10-08
MX23619A (es) 1993-10-01
KR910011894A (ko) 1991-08-07
PL165225B1 (pl) 1994-11-30
ZA909743B (en) 1991-08-28
NO176566C (no) 1995-04-26
LV5738A4 (lv) 1996-08-20
US5196438A (en) 1993-03-23
FI973895L (fi) 1997-10-06
DE69019481T2 (de) 1995-11-09
FI973895A0 (fi) 1997-10-06
GR3017114T3 (en) 1995-11-30
IL96550A (en) 1995-03-15
PL288201A1 (en) 1991-09-09
DZ1467A1 (fr) 2004-09-13
FI973895A7 (fi) 1997-10-06
FI905983L (fi) 1991-06-12
PT96145A (pt) 1991-09-30
ATE122661T1 (de) 1995-06-15
NO176566B (no) 1995-01-16
CN1052482A (zh) 1991-06-26
MX173630B (es) 1994-03-18
HU908076D0 (en) 1991-06-28
DK0432695T3 (da) 1995-09-11
GB9026776D0 (en) 1991-01-30
NL970013I2 (nl) 1997-09-01
NO905322L (no) 1991-06-12
GB8927913D0 (en) 1990-02-14
BR9006264A (pt) 1991-09-24
HUT56073A (en) 1991-07-29
CU22305A3 (es) 1995-01-31
HRP930341A2 (en) 1994-10-31
SI9012315B (sl) 1998-06-30
HRP930341B1 (en) 1998-12-31
CN1034805C (zh) 1997-05-07
ES2072959T3 (es) 1995-08-01
LU90014I2 (fr) 1997-01-31
HU207298B (en) 1993-03-29
HK129093A (en) 1993-12-03
EP0432695B1 (en) 1995-05-17
IE67523B1 (en) 1996-04-03
FI100883B (fi) 1998-03-13
CZ280558B6 (cs) 1996-02-14
FI905983A0 (fi) 1990-12-04
BG51452A3 (bg) 1993-05-14
MW8890A1 (en) 1991-03-13
IL96550A0 (en) 1991-09-16
ZW17490A1 (en) 1992-06-17
IS3651A7 (is) 1991-06-12
DE69019481D1 (de) 1995-06-22
ID1018B (id) 1996-10-18
PT96145B (pt) 1998-04-30
EP0432695A2 (en) 1991-06-19
EP0432695A3 (en) 1991-12-18
CA2030433C (en) 1997-10-21
LTIP862A (en) 1995-03-27
CA2030433A1 (en) 1991-06-12
NL970013I1 (nl) 1997-05-01
MTP1075B (en) 1991-07-31
LV5738B4 (lv) 1996-12-20
RO107942B1 (ro) 1994-01-31

Similar Documents

Publication Publication Date Title
DE4091597T (cg-RX-API-DMAC7.html)
IN172553B (cg-RX-API-DMAC7.html)
DE4091841T (cg-RX-API-DMAC7.html)
FR2645013B1 (cg-RX-API-DMAC7.html)
DE4092105T (cg-RX-API-DMAC7.html)
FR2641750B1 (cg-RX-API-DMAC7.html)
FR2642974B1 (cg-RX-API-DMAC7.html)
DE4090165T (cg-RX-API-DMAC7.html)
FR2645234B1 (cg-RX-API-DMAC7.html)
FR2641722B1 (cg-RX-API-DMAC7.html)
DE4090770T (cg-RX-API-DMAC7.html)
DE3991752T (cg-RX-API-DMAC7.html)
DE4092109T (cg-RX-API-DMAC7.html)
FR2643671B1 (cg-RX-API-DMAC7.html)
FR2642552B1 (cg-RX-API-DMAC7.html)
DE4091752T (cg-RX-API-DMAC7.html)
DE4090739T (cg-RX-API-DMAC7.html)
FR2644164B1 (cg-RX-API-DMAC7.html)
FR2652904B1 (cg-RX-API-DMAC7.html)
DE4090078T (cg-RX-API-DMAC7.html)
DE4042389A1 (cg-RX-API-DMAC7.html)
EP0668703A3 (cg-RX-API-DMAC7.html)
DE4091054T (cg-RX-API-DMAC7.html)
FR2644734B1 (cg-RX-API-DMAC7.html)
FR2642732B1 (cg-RX-API-DMAC7.html)